Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-30 12:44:51 Page View：8188

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B
Next article： Drug repurposing or repositioning? The language matters

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Head of FDA's diagnostics center, who led through Covid, retires

TimothyStenzelledtheFDA'sdiagnosticsdivisionduringtheCovid-19pandemic,astheagencyscrambledtopushthro

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Radiology is caught between AI's potential and concern for patients

AdobeRadiologyhaslongledthewayintheapplicationofartificialintelligenceinmedicine.Morethanthree-quart